For investors, biotech is a risky sector. One drug approval or denial can make or break a company’s fortunes. This is why biotech ETFs are a less risky way to play the sector, giving you exposure to a variety of companies and minimizing the negative impact of an FDA denial.

For more stories about biotech, visit our biotechnology category.

  • SPDR S&P Bioetch (NYSEArca: XBI)
  • iShares Nasdaq Biotechnology (NASDAQ: IBB)
  • First Trust Amex Biotechnology Fund (NYSEArca: FBT)

Tisha Guerrero contributed to this article.

Showing Page 2 of 2